Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2021-03-23 10:51 (678 d 21:44 ago) – Posting: # 22290
Views: 6,603

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
22,477 posts in 4,708 threads, 1,603 registered users;
17 visitors (0 registered, 17 guests [including 5 identified bots]).
Forum time: 08:35 CET (Europe/Vienna)

The mediocre teacher tells.
The good teacher explains.
The superior teacher demonstrates.
The great teacher inspires.    William Arthur Ward

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5